Onyx Pharmaceuticals Inc said on Thursday that its process of seeking a buyer for the company is "ongoing with multiple parties engaged."Onyx had previously rejected an unsolicited takeover offer from Amgen Inc as being too low.Reuters, citing three people familiar with the process, reported on Wednesday that Amgen was in advanced discussions to purchase Onyx at an increased offer of $130 per share, or about $9.5 billion, with the two sides working toward a possible announcement as soon as within the next week.On a conference call with analysts, Onyx Chief Executive Anthony Coles said "multiple parties" were still involved in the takeover talks.
Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Shares of AMGN fell by 1.8% or $-2.02/share to $110.38. In the past year, the shares have traded as low as $80.60 and as high as $114.95. On average, 3379480 shares of AMGN exchange hands on a given day and today's volume is recorded at 4758696.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. Shares of ONXX fell by 0.62% or $-0.79/share to $127.42. In the past year, the shares have traded as low as $66.37 and as high as $136.87. On average, 1872070 shares of ONXX exchange hands on a given day and today's volume is recorded at 2975844.
Source
